2017
HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer.
Ogden A, Bhattarai S, Green A, Aleskandarany M, Rakha E, Ellis I, Li X, Krishnamurti U, Janssen E, Jonsdottir K, Reid M, Rida P, Aneja R. HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 11612-11612. DOI: 10.1200/jco.2017.35.15_suppl.11612.Peer-Reviewed Original ResearchTNBC patientsDistant metastasisPrognostic valueBreast cancerCox proportional hazards regressionTriple-negative breast cancerProportional hazards regressionHigher immunohistochemical expressionTop upstream regulatorsMulti-institutional studyMann-Whitney U testCanonical pathwaysTop canonical pathwaysErbB family membersHER3 levelsPreclinical evidenceClinical outcomesHazards regressionHepatic fibrosisImmunohistochemical biomarkersImmunohistochemical expressionLuminal cytokeratinsMultivariable modelEGFR levelsFibrotic process
2016
CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition
Kapur N, Mir H, Clark III C, Krishnamurti U, Beech D, Lillard J, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. British Journal Of Cancer 2016, 114: 1343-1351. PMID: 27149649, PMCID: PMC4984452, DOI: 10.1038/bjc.2016.113.Peer-Reviewed Original ResearchConceptsColon cancerNodal statusCCR6 expressionTherapeutic optionsEMT markersExpression of CCR6Node-positive casesTNM staging systemUndefined molecular mechanismsPotential therapeutic targetNormal adjacent tissuesTissues/cellsMolecular mechanismsIdentification of markersAdjuvant chemotherapyAdvanced diseaseMolecular pathwaysDistant metastasisN-cadherinClinical associationsStaging systemMetastatic casesInvasive potentialΒ-cateninCancer cases